Expert Interviews

Along with her Fall Clinical 2026 sessions, Glynis Ablon, MD, discusses combining energy devices with PRP and exosomes, early extended release minoxidil results, and topical stem cell research.

Todd Schlesinger, MD, highlighted the new photodynamic therapy indication for superficial basal cell carcinoma, immunotherapy options for cutaneous squamous cell carcinoma, and sequential actinic keratosis therapy at Fall Clinical 2026.

Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of polypharmacy.

An independence-minded 72-year-old with hand arthritis and missed oral doses forces a reassessment of what a workable psoriasis regimen looks like once dexterity and daily routine become limiting factors.

At Fall Clinical 2026, Aaron Farberg, MD, reviewed gene expression profiling in atopic dermatitis and melanoma, and the Ameluz plus PDT approval for superficial basal cell carcinoma.

Adam Friedman, MD, discusses early psoriatic arthritis screening and why long-term data are critical to guiding treatment decisions.

At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls

At Fall Clinical 2026, Jennifer Hsiao, MD, discussed patient preference, comorbidities, and access guide HS treatment selection.

Ahmad Naim, MD, discussed clinician education, long-term data, and what is next in alopecia areata, HS, and psoriasis.

At Fall Clinical 2026, Christopher Bunick, MD, PhD, discussed topical and oral acne management, including tetracycline selection and micronized isotretinoin.

At Fall Clinical 2026, Glynis Ablon, MD, recommends body dysmorphic disorder screening and systematic documentation in aesthetics, plus early combination therapy for multifactorial alopecia.

At Fall Clinical 2026, Shannon Trotter, DO, reviews locally advanced and metastatic cutaneous squamous cell carcinoma, immune checkpoint inhibitors, and proposed Medicare cuts affecting skin cancer care.

Christopher Bunick, MD, PhD, presented long-term safety data for JAK inhibitors upadacitinib and abrocitinib in atopic dermatitis at Fall Clinical 2026.

Jennifer Hsiao, MD, explains how defining HS treatment response improves adherence and success.

At Fall Clinical 2026, Raj Chovatiya, MD, PhD, MSCI, urged clinicians to understand the data and consider systemic therapy in atopic dermatitis.

Whitney Tolpinrud, MD, discusses how personalized skin care can evolve from acne treatment toward prevention and skin longevity.

Behind each diagnosis is a patient whose work, recreation, and sense of normalcy have been quietly constrained. Personal accounts from both clinicians show why quality-of-life questions belong in every urticaria visit.

Strict photoprotection remains the foundation of EPP care, and only one therapy is approved worldwide. Earlier diagnosis and oral agents that lower protoporphyrin production emerge as the field's most pressing needs.

Years can pass between the first symptoms and a correct EPP diagnosis, and those years carry risk. The discussion links delayed recognition to protoporphyric hepatopathy, iron deficiency, and vitamin D deficiency.

Chronic inducible urticaria is more common than its limited recognition suggests, spans many distinct subtypes, and carries a substantial psychological toll. Accurate diagnosis depends on history and, ideally, standardized provocation testing.

Shannon Trotter, DO, discusses augmented intelligence in skin cancer detection, the approval of remibrutinib for symptomatic dermatographism, and her patient education podcast.

Whitney Tolpinrud, MD, discusses the evolution of personalized prescription skin care, patient expectations in the digital age, and clinical trends.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.

Distinct pharmacokinetic profiles, including volume of distribution, half-life, and time to steady state, differentiate the two approved hedgehog inhibitors and can be translated into patient-facing counseling during shared decision-making.

Multimodal planning for advanced basal cell carcinoma extends beyond labeled indications, with neoadjuvant hedgehog inhibition, adjuvant radiation, and immune checkpoint inhibitors each occupying a defined place in treatment sequencing.

Andrew Blauvelt, MD, MBA, discusses how to interpret head-to-head, indirect, and long-term efficacy data for emerging oral psoriasis therapies.

Setting realistic timelines and reading quality of life matter as much as counting lesions. The panel also flags a common pitfall: mistaking healing pigment changes for active disease.

Black box warnings, screening requirements, and real-world experience all shape which biologic fits a given patient. The panel applies these safety considerations directly to the first case.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), discusses diagnosed prevalence of AD and care access findings from the NEA's State of AD 2026 report.

Speed of onset and long-term durability are often treated as competing priorities. Dr. Armstrong argues they are not mutually exclusive, and details how cardiometabolic comorbidities and how emerging incretin-therapy data may extend treatment options beyond skin clearance alone.